Ibcasertib is an investigational new drug that is being evaluated to treat small-cell lung cancer. Ibcasertib inhibits several angiogenesis-related kinases, including VEGFR1, VEGFR2, VEGFR3, PDGFRα, and c-Kit, as well as the mitosis-related kinase Aurora B and the chronic inflammation-related kinase CSF-1R.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.